Designing nanomedicine to overcome therapeutic challenges in pregnancy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Pregnancy and Medication Impact · Pregnancy and preeclampsia studies · Pharmacological Effects and Toxicity Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (15)
Show source-provided references
1. Feghali, M., Venkataramanan, R. & Caritis, S. Pharmacokinetics of drugs in pregnancy. Semin. Perinatol. 39, 512–519 (2015).10.1053/j.semperi.2015.08.003 ↗
2. Sharma, A., Sah, N., Kannan, S. & Kannan, R. M. Targeted drug delivery for maternal and perinatal health: challenges and opportunities. Adv. Drug Deliv. Rev. 177, 113950 (2022).10.1016/j.addr.2021.113950 ↗
3. Figueroa-Espada, C. G., Hofbauer, S., Mitchell, M. J. & Riley, R. S. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy. Adv. Drug Deliv. Rev. 160, 244–261 (2020).10.1016/j.addr.2020.09.006 ↗
4. Shojaei, S. et al. Dynamic placenta-on-a-chip model for fetal risk assessment of nanoparticles intended to treat pregnancy-associated diseases. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166131 (2021).10.1016/j.bbadis.2021.166131 ↗
5. Scaffidi, J., Mol, B. & Keelan, J. The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. BJOG 124, 132–140 (2017).10.1111/1471-0528.14151 ↗
6. Chambers, C. D., Polifka, J. E. & Friedman, J. M. Drug safety in pregnant women and their babies: ignorance not bliss. Clin. Pharmacol. Ther. 83, 181–183 (2008).10.1038/sj.clpt.6100448 ↗
7. Cardonick, E. & Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol. 5, 283–291 (2004).10.1016/S1470-2045(04)01466-4 ↗
8. Galbally, M., Snellen, M. & Power, J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther. Adv. Drug Saf. 5, 100–109 (2014).10.1177/2042098614522682 ↗
9. Costantine, M. M. Physiologic and pharmacokinetic changes in pregnancy. Front. Pharmacol. 5, 65 (2014).10.3389/fphar.2014.00065 ↗
10. Al-Enazy, S., Ali, S., Albekairi, N., El-Tawil, M. & Rytting, E. Placental control of drug delivery. Adv. Drug Deliv. Rev. 116, 63–72 (2017).10.1016/j.addr.2016.08.002 ↗
11. Huang, Y., Wang, J., Jiang, K. & Chung, E. J. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions. J Control. Release 334, 127–137 (2021).10.1016/j.jconrel.2021.04.016 ↗
12. Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862–1894 (2021).10.1021/acs.molpharmaceut.1c00046 ↗
13. Gao, W., Chan, J. & Farokhzad, O. C. pH-responsive nanoparticles for drug delivery. Mol. Pharm. 7, 1913–1920 (2010).10.1021/mp100253e ↗
14. Zinger, A. et al. Enhancing inflammation targeting using tunable leukocyte-based biomimetic nanoparticles. ACS Nano 15, 6326–6339 (2021).10.1021/acsnano.0c05792 ↗
15. Zinger, A. Unleashing the potential of cell biomimetic nanoparticles: strategies and challenges in their design and fabrication for therapeutic applications. J. Control. Release 358, 591–600 (2023).10.1016/j.jconrel.2023.04.040 ↗